ALDH2 polymorphism rs671 is a predictor of PD-1/PD-L1 inhibitor efficacy against thoracic malignancies

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1471-2407

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: ALDH2 polymorphism rs671 is a predictor of PD-1/PD-L1 inhibitor efficacy against thoracic malignancies ; volume:21 ; number:1 ; day:22 ; month:5 ; year:2021 ; pages:1-11 ; date:12.2021
BMC cancer ; 21, Heft 1 (22.5.2021), 1-11, 12.2021

Creator: Matsumoto, Akiko
Nakashima, Chiho
Kimura, Shinya
Sueoka, Eizaburo
Aragane, Naoko

Contributor: SpringerLink (Online service)

DOI: 10.1186/s12885-021-08329-y

URN: urn:nbn:de:101:1-2021091919510556479947

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:38 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Matsumoto, Akiko
Nakashima, Chiho
Kimura, Shinya
Sueoka, Eizaburo
Aragane, Naoko
SpringerLink (Online service)

Other Objects (12)

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Regulatory mechanisms of PD-1/PD-L1 in cancers

The PD-1:PD-L1 axis in Inflammatory Arthritis

PD-1/PD-L1 binding studies using microscale thermophoresis

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy

Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit

The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Regulatory mechanisms of PD-1/PD-L1 in cancers

The PD-1:PD-L1 axis in Inflammatory Arthritis

PD-1/PD-L1 binding studies using microscale thermophoresis

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy

Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit

The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Regulatory mechanisms of PD-1/PD-L1 in cancers

The PD-1:PD-L1 axis in Inflammatory Arthritis

PD-1/PD-L1 binding studies using microscale thermophoresis

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy

Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit

The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

ALDH2 polymorphism rs671 is a predictor of PD-1/PD-L1 inhibitor efficacy against thoracic malignancies

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Regulatory mechanisms of PD-1/PD-L1 in cancers

The PD-1:PD-L1 axis in Inflammatory Arthritis

PD-1/PD-L1 binding studies using microscale thermophoresis

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy

Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit

The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Regulatory mechanisms of PD-1/PD-L1 in cancers

The PD-1:PD-L1 axis in Inflammatory Arthritis

PD-1/PD-L1 binding studies using microscale thermophoresis

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy

Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit

The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Regulatory mechanisms of PD-1/PD-L1 in cancers

The PD-1:PD-L1 axis in Inflammatory Arthritis

PD-1/PD-L1 binding studies using microscale thermophoresis

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy

Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit

The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Related objects

Reset password